Chemotherapy Rewrites Ovarian Cancer Drug Sensibility Without Touching the Genome
Patient-derived ovarian cancer organoids show that brief chemotherapy exposure reshapes sensitivity to second-line drugs such as cediranib and topotecan without ...
Patient-derived ovarian cancer organoids show that brief chemotherapy exposure reshapes sensitivity to second-line drugs such as cediranib and topotecan without ...
A comprehensive analysis of 136 registered clinical trials reveals that therapeutic vaccines for ovarian cancer have advanced steadily for three ...
A new study shows that inhibiting the kinase PTK6 with the drug tilfrinib suppresses the proliferation and migration of ovarian ...
In a discovery that is already rippling across the cancer research community, scientists in China have found that a common ...
A rare ovarian tumor that can transform the body with male-pattern hormonal changes may be compatible with fertility preservation in ...
In a groundbreaking phase 2 clinical trial, researchers have demonstrated the efficacy of olaparib, a PARP inhibitor, in treating metastatic ...
Ovarian cancer continues to pose significant challenges in gynecological oncology, particularly regarding its treatment and management strategies. The introduction of ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine